Advertisement

Baseline Assessment

  • Lawrence M. Friedman
  • Curt D. Furberg
  • David L. DeMets
Chapter

Abstract

In clinical trials, baseline refers to the status of a participant before the start of intervention. Baseline data may be measured by interview, questionnaire, physical examination, laboratory tests, and procedures. Measurement need not be only numerical in nature. It can also mean classification of study participants into categories based on factors such as absence or presence of some trait or condition.

Keywords

Chronic Obstructive Pulmonary Disease Baseline Data Baseline Comparability Baseline Factor Subgroup Finding 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Hall JC, Hall JL. Baseline comparisons in surgical trials. ANZ J Surg 2002;72:567–569.CrossRefGoogle Scholar
  2. 2.
    Altman DG, Doré CJ. Randomization and baseline comparisons in clinical trials. Lancet 1990;335:149–153.CrossRefGoogle Scholar
  3. 3.
    Lachin JM. Properties of simple randomization in clinical trials. Control Clin Trials 1988;9:312–326.CrossRefGoogle Scholar
  4. 4.
    Harmatz P, Giugliani R, Schwartz I, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or RHASB) and follow-on, open-label extension study. J Pediatr 2006;148:533–539.CrossRefGoogle Scholar
  5. 5.
    Sano M, Ernesto C, Thomas RG, et al. for the Members of the Alzheimer’s Disease Cooperative Study. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s Disease. N Engl J Med 1997;336:1216–1222.Google Scholar
  6. 6.
    Aspirin Myocardial Infarction Study Research Group. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 1980;243:661–669.CrossRefGoogle Scholar
  7. 7.
    The Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 1978;299:53–59.CrossRefGoogle Scholar
  8. 8.
    Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy – I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81–106.Google Scholar
  9. 9.
    Ridker PM, Cook NR, Lee I-M, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293–1304.CrossRefGoogle Scholar
  10. 10.
    Kahn SE, Haffner SM, Heise MA, et al. for the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427–2443.Google Scholar
  11. 11.
    Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 2005;366:1279–1289.CrossRefGoogle Scholar
  12. 12.
    Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009;180:32–39.CrossRefGoogle Scholar
  13. 13.
    Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000;355:1064–1069.CrossRefGoogle Scholar
  14. 14.
    Johnson JA, Boerwinkle E, Zineh I, et al. Pharmacogenomics of antihypertensive drugs: Rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am Heart J 2009;157:442–449.CrossRefGoogle Scholar
  15. 15.
    Grant SF, Hakonarson H. Recent development in pharmacogenomics: from candidate genes to genome-wide association studies. Expert Rev Mol Diagn 2007;7:371–393.CrossRefGoogle Scholar
  16. 16.
    Donnelly P. Progress and challenges in genome-wide association studies in humans. Nature 2008;456:728–731.CrossRefGoogle Scholar
  17. 17.
    Nelson MR, Bacanu S-A, Mosteller M, et al. Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. Pharmacogenomics J 2009;9:23–33.CrossRefGoogle Scholar
  18. 18.
    The SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy – A genomewide study. N Engl J Med 2008;359:789–799.CrossRefGoogle Scholar
  19. 19.
    Coronary Drug Project Research Group. Factors influencing long-term prognosis after recovery from myocardial infarction – three year findings of the Coronary Drug Project. J Chronic Dis 1974;27:267–285.CrossRefGoogle Scholar
  20. 20.
    James KE. Regression toward the mean in uncontrolled clinical studies. Biometrics 1973;29:121–130.CrossRefGoogle Scholar
  21. 21.
    Schor SS. The floor-and-ceiling effect. JAMA 1969;207:120.CrossRefGoogle Scholar
  22. 22.
    Cutter GR. Some examples for teaching regression toward the mean from a sampling viewpoint. Am Stat 1976;30:194–197.Google Scholar
  23. 23.
    European Coronary Surgery Study Group. Coronary-artery bypass surgery in stable angina pectoris: survival at two years. Lancet 1979;1:889–893.Google Scholar
  24. 24.
    The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673–682. (Correction 1994;331:277).CrossRefGoogle Scholar
  25. 25.
    Tilley BC, Lyden PD, Brott TG, et al. for the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Total quality improvement method for reduction of delays between emergency department admission and treatment of acute ischemic stroke. Arch Neurol 1997;54:1466–1474.Google Scholar
  26. 26.
    Davis BR, Cutler JA, Gordon DJ, et al. for the ALLHAT Research Group. Rationale and design of the Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT). Am J Hypertens 1996;9:342–360.Google Scholar
  27. 27.
    Kollef MH, Afessa B, Anzueto A, et al. for the NASCENT Investigation Group. Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia. The NASCENT randomized trial. JAMA 2008;300:805–813.Google Scholar
  28. 28.
    Chastre J. Preventing ventilator-associated pneumonia. Could silver-coated endotracheal tubes be the answer? (Editorial). JAMA 2008;300:842–844.CrossRefGoogle Scholar
  29. 29.
    Senn S. Testing for baseline balance in clinical trials. Stat Med 1994;13:1715–1726.CrossRefGoogle Scholar
  30. 30.
    Steyerberg EW, Bossuyt PMM, Lee KL. Clinical trials in acute myocardial infarction: Should we adjust for baseline characteristics? Am Heart J 2000;139:745–751.CrossRefGoogle Scholar
  31. 31.
    Roberts C, Torgerson DJ. Understanding controlled trials. Baseline imbalance in randomised controlled trials. Br Med J 1999;319:185.CrossRefGoogle Scholar
  32. 32.
    Burgess DC, Gebski VJ, Keech AC. Baseline data in clinical trials. MJA 2003;179:105–107.Google Scholar

Copyright information

© Springer New York 2010

Authors and Affiliations

  • Lawrence M. Friedman
    • 1
  • Curt D. Furberg
    • 2
  • David L. DeMets
    • 3
  1. 1.BethesdaUSA
  2. 2.School of MedicineWake Forest UniversityWinston-SalemUSA
  3. 3.Department of Biostatistics & Medical InformaticsUniversity of WisconsinMadisonUSA

Personalised recommendations